Dcode This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
All four managing partners at Dcode Capital are women a rarity in the world of venture capital.
The four have expertise in connecting investors and startups with deep-pocketed government agencies.
CEO Meagan Metzger says Dcode brings partners together in an atmosphere of psychological safety.
The four women who lead Dcode Capital, the investment arm of the Washington, DC, startup accelerator Dcode, pull together three very different worlds. They work closely with the federal government, startups, and venture capitalists – industries that also happen to be traditionally dominated by men.
Product and service reviews are conducted independently by our editorial team, but we sometimes make money when you click on links.Learn more.
What Employers Need to Know About Ban the Box
Alison Grillo
Jan 25, 2021
It is important to examine your company s policies for seeking information on criminal history of job candidates. Many states and cities have legislation on when this information can be requested.
Landing a job can be a difficult process, and it s even harder for those who have a criminal history. For years, most job applications asked whether the candidate had ever been convicted of a crime. Job seekers having to answer this question, without the ability to provide any context to their answer, often gave employers a quick reason to discard the application and move on to the next.
Welldoc Submits 510(k) for Bolus and Premixed Insulin Titration Program as Part of BlueStar®
Welldoc Submits 510(k) for Bolus and Premixed Insulin Titration Program as Part of BlueStar® Welldoc, a trailblazer in digital health that is revolutionizing chronic condition management to help transform lives, today announced the filing of its ninth 510(k) with the U.S. Food and Drug Administration (FDA) for BlueStar, an FDA-cleared digital health solution for diabetes. With the filing, BlueStar looks to add bolus and premixed insulin titration for type 2 diabetes to its comprehensive diabetes platform. In June, Welldoc announced FDA clearance for the BlueStar Insulin Adjustment Program for basal insulin titration. This current submission would expand insulin dosing support to include most types of insulin. The 510(k) was submitted on Nov 23, 2020.